治疗早期头外动脉静脉形形的特拉美丁尼布:一个多中心,前性,单臂试点研究
1Department of Interventional Therapy, Multidisciplinary Team of Vascular Anomalies, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China.
Journal of the American Academy of Dermatology
|July 19, 2025
概括
特拉梅提尼布在治疗儿童早期脑外动脉静脉形形 (eAVM) 的短期有效性和安全性. 这项试点研究表明了积极的临床反应和良好的耐受性,需要进一步调查长期结果.
科学领域:
- 血管医学 血管医学
- 儿科瘤学 儿科瘤学
- 药理学 药理学是指药理学的学科.
背景情况:
- 额外动脉静脉形 (eAVMs) 是一种进展性血管异常,具有有限的治疗常规疗法.
- 对于早期的eAVMs,特别是儿童的有效治疗方法仍然很少.
- 特拉美提尼布对儿童早期eAVM的安全性和有效性尚未得到充分证实.
研究的目的:
- 评估特拉梅西尼布在治疗早期eAVMs治疗中的疗效和安全性.
- 为了评估12个月的治疗结果.
主要方法:
- 一项试点研究涉及早期eAVM患者,他们接受了至少12个月的特拉美丁尼布治疗.
- 临床和放射学随访,包括定量 (皮肤温度,峰值动脉速度,皮肤颜色) 和定性 (数字减去血管造影) 评估.
主要成果:
- 观察到显著的临床改善:53.5%的平均皮肤病变变白化,皮肤温度降低1°C,动脉血流速度降低74%的峰值,50%的达到了50%以上的脱细胞化.
- 患有KRAS/MAP2K1突变的患者比患有RASA1/EPHB4突变的患者有更大的改善.
- 特拉美替尼布耐受性良好,大多数不良事件为1/2级.
结论:
- 特拉美替尼布在治疗早期eAVMs的短期有效性和安全性上得到了证明.
- 需要进行进一步的研究,以确定特拉美替尼对eAVM的长期有效性和安全性.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
226
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
226
01:29Venous Thrombosis III: Interprofessional Care
23
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
23
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
260
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
260